107.50Open107.50Pre Close0 Volume0 Open Interest400.00Strike Price0.00Turnover94.46%IV-15.28%PremiumDec 20, 2024Expiry Date146.26Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9765Delta0.0016Gamma1.73Leverage Ratio-0.0517Theta-0.0754Rho-1.69Eff Leverage0.0332Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet